In this study, the investigators aimed to evaluate the maternal and fetal effect of sugammadex in pregnant patients undergoing a non-obstetric surgery. The investigators mainly focused on the short- and long-term adverse effects such as an abortion or a teratogenic effect and that may occur in fetus and the adverse effects that may be seen in mother.
Since the approval in Europe in 2008, sugammadex has been widely studied among pregnant patients in the context of cesarean deliveries. However, the use of sugammadex in pregnant patients undergoing a non-obstetric surgery is not clearly defined. The package insert indicates that there are no data on its use in pregnant women regarding the drug-associated risks. There are some questions raised, and answers needed from the scientific community about the maternal and fetal effect of sugammadex administered in pregnant patients. This is a retrospective case-control cohort study which was conducted in a single-center territory university hospital. The investigators used the hospital information management system for determining the patients that are eligible for inclusion. Patients operated between January 2017 and june 2022 were included in the study. Patient data was obtained by manual review of anesthesia charts of eligible patients. Pregnant patients who underwent a non-pregnancy surgical intervention within the study period were included in the study.
Study Type
OBSERVATIONAL
Enrollment
26
Sakarya University Training and Research Hospital
Serdivan, Sakarya, Turkey (Türkiye)
Fetal outcome
Determined by using APGAR score.
Time frame: one week postoperatively
Preterm labor
Labor that starts before 37 completed weeks of pregnancy.
Time frame: Labor that starts before 37 completed weeks of pregnancy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.